CoChat

Targeting β-Cell Mass in Type 2 Diabetes: Promise and Limitations of New Drugs Based on Incretins

Open access
Salehi, Marzieh, Aulinger, Benedikt A., D'Alessio, David A. · 2008 · Endocrine Reviews
Cited by 109

The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.

Abstract

Progressive insulin secretory defects, due to either functional abnormalities of the pancreatic β-cells or a reduction in β-cell mass, are the cornerstone of type 2 diabetes. Incretin-based drugs hold the potential to improve glucose tolerance by immediate favorable effect on β-cell physiology as well as by expanding or at least maintaining β-cell mass, which may delay the progression of the disease. Long-term studies in humans are needed to elaborate on these effects.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/er.2007-0031

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 112

  1. Porte Jr, 1991, Banting lecture 1990. β-Cells in type II diabetes mellitus., Diabetes, 40, 166, 10.2337/diabetes.40.2.166 · DOI
  2. Kahn, 2001, Clinical review 135: the importance of β-cell failure in the development and progression of type 2 diabetes., J Clin Endocrinol Metab, 86, 4047
  3. Byrne, 1996, Elevated plasma glucose 2 h postchallenge predicts defects in β-cell function, Am J Physiol, 270, E572
  4. Sakuraba, 2002, Reduced β-cell mass and expression of oxidative stress-related DNA damage in the islet of Japanese Type II diabetic patients., Diabetologia, 45, 85, 10.1007/s125-002-8248-z · DOI · Paper page
  5. Yoon, 2003, Selective β-cell loss and α-cell expansion in patients with type 2 diabetes mellitus in Korea., J Clin Endocrinol Metab, 88, 2300, 10.1210/jc.2002-020735 · DOI · Paper page
  6. Matveyenko, 2006, β-Cell deficit due to increased apoptosis in the human islet amyloid polypeptide transgenic (HIP) rat recapitulates the metabolic defects present in type 2 diabetes., Diabetes, 55, 2106, 10.2337/db05-1672 · DOI · Paper page
  7. Robertson, 2001, Prevention of diabetes for up to 13 years by autoislet transplantation after pancreatectomy for chronic pancreatitis., Diabetes, 50, 47, 10.2337/diabetes.50.1.47 · DOI · Paper page
  8. Rossetti, 1990, Glucose toxicity., Diabetes Care, 13, 610, 10.2337/diacare.13.6.610 · DOI · Paper page
  9. Maedler, 2002, Glucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets., J Clin Invest, 110, 851, 10.1172/JCI200215318 · DOI · Paper page
  10. Leahy, 1988, Minimal chronic hyperglycemia is a critical determinant of impaired insulin secretion after an incomplete pancreatectomy., J Clin Invest, 81, 1407, 10.1172/JCI113470 · DOI · Paper page
  11. Donath, 2004, Decreased β-cell mass in diabetes: significance, mechanisms and therapeutic implications., Diabetologia, 47, 581, 10.1007/s00125-004-1336-4 · DOI · Paper page
  12. Paty, 2004, Toward development of imaging modalities for islets after transplantation: insights from the National Institutes of Health Workshop on β Cell Imaging., Transplantation, 77, 1133, 10.1097/01.TP.0000113231.90613.0E · DOI
  13. Hosokawa, 1996, Mechanism of impaired glucose-potentiated insulin secretion in diabetic 90% pancreatectomy rats. Study using glucagonlike peptide-1 (7-37)., J Clin Invest, 97, 180, 10.1172/JCI118387 · DOI
  14. Bonner-Weir, 2000, Islet growth and development in the adult., J Mol Endocrinol, 24, 297, 10.1677/jme.0.0240297 · DOI · Paper page
  15. Sorenson, 1987, Prolactin (in vitro) decreases the glucose stimulation threshold, enhances insulin secretion, and increases dye coupling among islet B cells., Endocrinology, 121, 1447, 10.1210/endo-121-4-1447 · DOI
  16. Bruning, 1997, Development of a novel polygenic model of NIDDM in mice heterozygous for IR and IRS-1 null alleles., Cell, 88, 561, 10.1016/S0092-8674(00)81896-6 · DOI · Paper page
  17. Lee, 1989, Compensatory adaption to partial pancreatectomy in the rat., Endocrinology, 124, 1571, 10.1210/endo-124-3-1571 · DOI
  18. Creutzfeldt, 1985, New developments in the incretin concept., Diabetologia, 28, 565, 10.1007/BF00281990 · DOI · Paper page
  19. Schirra, 1996, Gastric emptying and release of incretin hormones after glucose ingestion in humans., J Clin Invest, 97, 92, 10.1172/JCI118411 · DOI · Paper page
  20. Ebert, 1987, Gastrointestinal peptides and insulin secretion., Diabetes Metab Rev, 3, 1, 10.1002/dmr.5610030101 · DOI
  21. Finegood, 1995, Dynamics of β-cell mass in the growing rat pancreas. Estimation with a simple mathematical model., Diabetes, 44, 249, 10.2337/diab.44.3.249 · DOI · Paper page
  22. Bollag, 2000, Osteoblast-derived cells express functional glucose-dependent insulinotropic peptide receptors., Endocrinology, 141, 1228, 10.1210/endo.141.3.7366 · DOI · Paper page
  23. Irwin, 2004, Effects of short-term chemical ablation of the GIP receptor on insulin secretion, islet morphology and glucose homeostasis in mice., Biol Chem, 385, 845, 10.1515/BC.2004.110 · DOI · Paper page
  24. Tseng, 1996, Postprandial stimulation of insulin release by glucose-dependent insulinotropic polypeptide (GIP). Effect of a specific glucose-dependent insulinotropic polypeptide receptor antagonist in the rat., J Clin Invest, 98, 2440, 10.1172/JCI119060 · DOI · Paper page
  25. Kieffer, 1999, The glucagon-like peptides., Endocr Rev, 20, 876, 10.1210/edrv.20.6.0385 · DOI · Paper page
  26. Bullock, 1996, Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide- 1 receptor., Endocrinology, 137, 2968, 10.1210/endo.137.7.8770921 · DOI · Paper page
  27. Nakagawa, 2004, Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells., Auton Neurosci, 110, 36, 10.1016/j.autneu.2003.11.001 · DOI · Paper page
  28. Gromada, 1998, Glucagon-like peptide 1 (7-36) amide stimulates exocytosis in human pancreatic β-cells by both proximal and distal regulatory steps in stimulus-secretion coupling., Diabetes, 47, 57, 10.2337/diab.47.1.57 · DOI · Paper page
  29. Wang, 1997, Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats., J Clin Invest, 99, 2883, 10.1172/JCI119482 · DOI · Paper page
  30. Burcelin, 2001, Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor., Diabetes, 50, 1720, 10.2337/diabetes.50.8.1720 · DOI · Paper page
  31. Buteau, 2003, Glucagon-like peptide 1 induces pancreatic β-cell proliferation via transactivation of the epidermal growth factor receptor., Diabetes, 52, 124, 10.2337/diabetes.52.1.124 · DOI · Paper page
  32. De Leon, 2003, Role of endogenous glucagon-like peptide-1 in islet regeneration after partial pancreatectomy., Diabetes, 52, 365, 10.2337/diabetes.52.2.365 · DOI · Paper page
  33. Pederson, 1998, Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor −/− mice., Diabetes, 47, 1046, 10.2337/diabetes.47.7.1046 · DOI · Paper page
  34. Falko, 1975, Gastric inhibitory polypeptide (GIP) stimulated by fat ingestion in man., J Clin Endocrinol Metab, 41, 260, 10.1210/jcem-41-2-260 · DOI · Paper page
  35. Ross, 1978, Effects of ingestion of triglyceride or galactose on secretion of gastric inhibitory polypeptide and on responses to intravenous glucose in normal and diabetic subjects., Diabetes, 27, 327, 10.2337/diab.27.3.327 · DOI · Paper page
  36. Hansen, 2004, Neural regulation of glucagon-like peptide-1 secretion in pigs, Am J Physiol Endocrinol Metab, 287, E939, 10.1152/ajpendo.00197.2004 · DOI · Paper page
  37. Rocca, 1999, Role of the vagus nerve in mediating proximal nutrient-induced glucagon-like peptide-1 secretion., Endocrinology, 140, 1687, 10.1210/endo.140.4.6643 · doi:10.1210/endo.140.4.6643 · Paper page
  38. Vilsboll, 2001, Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients., Diabetes, 50, 609, 10.2337/diabetes.50.3.609 · DOI · Paper page
  39. Hansen, 1999, Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine., Endocrinology, 140, 5356, 10.1210/endo.140.11.7143 · DOI · Paper page
  40. Gault, 2005, Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes., Diabetes, 54, 2436, 10.2337/diabetes.54.8.2436 · DOI · Paper page
  41. Xie, 2007, Glucose-dependent insulinotropic peptide-overexpressing transgenic mice have increased bone mass., Bone, 40, 1352, 10.1016/j.bone.2007.01.007 · DOI · Paper page
  42. Schirra, 2006, Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans., Gut, 55, 243, 10.1136/gut.2004.059741 · DOI · Paper page
  43. Nauck, 1997, Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans, Am J Physiol, 273, E981
  44. D'Alessio, 1994, Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal., J Clin Invest, 93, 2263, 10.1172/JCI117225 · DOI · Paper page
  45. Egan, 2002, Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state., J Clin Endocrinol Metab, 87, 3768, 10.1210/jcem.87.8.8743 · doi:10.1210/jcem.87.8.8743 · Paper page
  46. Krarup, 1988, Immunoreactive gastric inhibitory polypeptide., Endocr Rev, 9, 122, 10.1210/edrv-9-1-122 · DOI · Paper page
  47. Orskov, 1991, Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine., J Clin Invest, 87, 415, 10.1172/JCI115012 · DOI · Paper page
  48. Fukase, 1995, Response of truncated glucagon-like peptide-1 and gastric inhibitory polypeptide to glucose ingestion in non-insulin dependent diabetes mellitus. Effect of sulfonylurea therapy., Acta Diabetol, 32, 165, 10.1007/BF00838486 · DOI
  49. Vaag, 1996, Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM)–evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins., Eur J Endocrinol, 135, 425, 10.1530/eje.0.1350425 · DOI · Paper page
  50. Toft-Nielsen, 2001, Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients., J Clin Endocrinol Metab, 86, 3717, 10.1210/jcem.86.8.7750 · DOI · Paper page
  51. Knop, 2007, Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state?, Diabetes, 56, 1951, 10.2337/db07-0100 · DOI · Paper page
  52. Ryskjaer, 2006, Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake., Eur J Endocrinol, 155, 485, 10.1530/eje.1.02221 · DOI · Paper page
  53. O'Donovan, 2004, Effect of variations in small intestinal glucose delivery on plasma glucose, insulin, and incretin hormones in healthy subjects and type 2 diabetes., J Clin Endocrinol Metab, 89, 3431, 10.1210/jc.2004-0334 · DOI · Paper page
  54. Elahi, 1994, The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects., Regul Pept, 51, 63, 10.1016/0167-0115(94)90136-8 · DOI · Paper page
  55. Krarup, 1987, Effect of porcine gastric inhibitory polypeptide on β-cell function in type I and type II diabetes mellitus., Metabolism, 36, 677, 10.1016/0026-0495(87)90153-3 · DOI
  56. Meier, 2005, Secretion of incretin hormones and the insulinotropic effect of gastric inhibitory polypeptide in women with a history of gestational diabetes., Diabetologia, 48, 1872, 10.1007/s00125-005-1863-7 · DOI
  57. Meier, 2004, Stimulation of insulin secretion by intravenous bolus injection and continuous infusion of gastric inhibitory polypeptide in patients with type 2 diabetes and healthy control subjects, Diabetes, 53, S220, 10.2337/diabetes.53.suppl_3.S220 · DOI · Paper page
  58. Rachman, 1996, Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM., Diabetes, 45, 1524, 10.2337/diab.45.11.1524 · DOI · Paper page
  59. Rachman, 1997, Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM., Diabetologia, 40, 205, 10.1007/s001250050664 · DOI · Paper page
  60. Ahren, 1997, Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus., J Clin Endocrinol Metab, 82, 473
  61. Dor, 2006, β-Cell proliferation is the major source of new pancreatic β cells., Nat Clin Pract Endocrinol Metab, 2, 242, 10.1038/ncpendmet0187 · DOI
  62. Teta, 2007, Growth and regeneration of adult β cells does not involve specialized progenitors., Dev Cell, 12, 817, 10.1016/j.devcel.2007.04.011 · DOI · Paper page
  63. Skoglund, 2000, Glucagon-like peptide 1 stimulates insulin gene promoter activity by protein kinase A-independent activation of the rat insulin I gene cAMP response element., Diabetes, 49, 1156, 10.2337/diabetes.49.7.1156 · DOI · Paper page
  64. Wang, 2001, Glucagon-like peptide-1 causes pancreatic duodenal homeobox-1 protein translocation from the cytoplasm to the nucleus of pancreatic β-cells by a cyclic adenosine monophosphate/protein kinase A-dependent mechanism., Endocrinology, 142, 1820, 10.1210/endo.142.5.8128 · DOI · Paper page
  65. Holz, 2006, Cell physiology of cAMP sensor Epac., J Physiol, 577, 5, 10.1113/jphysiol.2006.119644 · DOI · Paper page
  66. Buteau, 2001, Protein kinase Cζ activation mediates glucagon-like peptide-1-induced pancreatic β-cell proliferation., Diabetes, 50, 2237, 10.2337/diabetes.50.10.2237 · DOI · Paper page
  67. Wang, 2002, Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice., Diabetologia, 45, 1263, 10.1007/s00125-002-0828-3 · DOI · Paper page
  68. Wang, 2005, Suppression of Pdx-1 perturbs proinsulin processing, insulin secretion and GLP-1 signalling in INS-1 cells., Diabetologia, 48, 720, 10.1007/s00125-005-1692-8 · DOI
  69. Bregenholt, 2005, The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits β-cell apoptosis in vitro., Biochem Biophys Res Commun, 330, 577, 10.1016/j.bbrc.2005.03.013 · DOI · Paper page
  70. Lawrence, 2002, NFAT regulates insulin gene promoter activity in response to synergistic pathways induced by glucose and glucagon-like peptide-1., Diabetes, 51, 691, 10.2337/diabetes.51.3.691 · DOI · Paper page
  71. Heit, 2006, Calcineurin/NFAT signalling regulates pancreatic β-cell growth and function., Nature, 443, 345, 10.1038/nature05097 · DOI · Paper page
  72. Hui, 2001, Glucagon-like peptide 1 induces differentiation of islet duodenal homeobox-1-positive pancreatic ductal cells into insulin-secreting cells., Diabetes, 50, 785, 10.2337/diabetes.50.4.785 · DOI · Paper page
  73. Bulotta, 2002, Cultured pancreatic ductal cells undergo cell cycle re-distribution and β-cell-like differentiation in response to glucagon-like peptide-1., J Mol Endocrinol, 29, 347, 10.1677/jme.0.0290347 · DOI · Paper page
  74. Abraham, 2002, Insulinotropic hormone glucagon-like peptide-1 differentiation of human pancreatic islet-derived progenitor cells into insulin- producing cells., Endocrinology, 143, 3152, 10.1210/endo.143.8.8973 · DOI · Paper page
  75. Gomez, 2002, cAMP-dependent protein kinase and Ca2+ influx through L-type voltage-gated calcium channels mediate Raf-independent activation of extracellular regulated kinase in response to glucagon-like peptide-1 in pancreatic β-cells., J Biol Chem, 277, 48146, 10.1074/jbc.M209165200 · DOI · Paper page
  76. Stoffers, 2000, Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas., Diabetes, 49, 741, 10.2337/diabetes.49.5.741 · DOI · Paper page
  77. Xu, 1999, Exendin-4 stimulates both β-cell replication and neogenesis, resulting in increased β-cell mass and improved glucose tolerance in diabetic rats., Diabetes, 48, 2270, 10.2337/diabetes.48.12.2270 · DOI · Paper page
  78. Hui, 2003, Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5′-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway., Endocrinology, 144, 1444, 10.1210/en.2002-220897 · DOI · Paper page
  79. Pospisilik, 2002, Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and β-cell glucose responsiveness in VDF (fa/fa) Zucker rats., Diabetes, 51, 943, 10.2337/diabetes.51.4.943 · DOI · Paper page
  80. Doyle, 2007, Mechanisms of action of glucagon-like peptide 1 in the pancreas., Pharmacol Ther, 113, 546, 10.1016/j.pharmthera.2006.11.007 · DOI · Paper page
  81. Perfetti, 2000, Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats., Endocrinology, 141, 4600, 10.1210/endo.141.12.7806 · doi:10.1210/endo.141.12.7806 · Paper page
  82. Soltani, 2007, In vivo expression of GLP-1/IgG-Fc fusion protein enhances β-cell mass and protects against streptozotocin-induced diabetes., Gene Ther, 14, 981, 10.1038/sj.gt.3302944 · DOI
  83. Tourrel, 2001, Glucagon-like peptide-1 and exendin-4 stimulate β-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age., Diabetes, 50, 1562, 10.2337/diabetes.50.7.1562 · DOI · Paper page
  84. Sharma, 2006, Exendin-4 treatment improves metabolic control after rat islet transplantation to athymic mice with streptozotocin-induced diabetes., Diabetologia, 49, 1247, 10.1007/s00125-006-0251-2 · DOI
  85. Suen, 2006, In vivo treatment with glucagon-like peptide 1 promotes the graft function of fetal islet-like cell clusters in transplanted mice., Int J Biochem Cell Biol, 38, 951, 10.1016/j.biocel.2005.08.005 · doi:10.1016/j.biocel.2005.08.005
  86. Wideman, 2006, Improving function and survival of pancreatic islets by endogenous production of glucagon-like peptide 1 (GLP-1)., Proc Natl Acad Sci USA, 103, 13468, 10.1073/pnas.0600655103 · DOI · Paper page
  87. Ghofaili, 2007, Effect of exenatide on β cell function after islet transplantation in type 1 diabetes., Transplantation, 83, 24, 10.1097/01.tp.0000251379.46596.2d · DOI · Paper page
  88. Amiranoff, 1984, Functional GIP receptors in a hamster pancreatic β cell line, In 111: specific binding and biological effects., Biochem Biophys Res Commun, 123, 671, 10.1016/0006-291X(84)90281-X · DOI
  89. Kashima, 2001, Critical role of cAMP-GEFII–Rim2 complex in incretin-potentiated insulin secretion., J Biol Chem, 276, 46046, 10.1074/jbc.M108378200 · DOI · Paper page
  90. Trumper, 2001, Glucose-dependent insulinotropic polypeptide is a growth factor for β (INS-1) cells by pleiotropic signaling., Mol Endocrinol, 15, 1559
  91. Ehses, 2003, Glucose-dependent insulinotropic polypeptide promotes β-(INS-1) cell survival via cyclic adenosine monophosphate-mediated caspase-3 inhibition and regulation of p38 mitogen-activated protein kinase., Endocrinology, 144, 4433, 10.1210/en.2002-0068 · DOI · Paper page
  92. Trumper, 2002, Mechanisms of mitogenic and anti-apoptotic signaling by glucose-dependent insulinotropic polypeptide in β (INS-1)-cells., J Endocrinol, 174, 233, 10.1677/joe.0.1740233 · DOI · Paper page
  93. Conarello, 2003, Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance., Proc Natl Acad Sci USA, 100, 6825, 10.1073/pnas.0631828100 · DOI · Paper page
  94. Amori, 2007, Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis., JAMA, 298, 194, 10.1001/jama.298.2.194 · DOI · Paper page
  95. Harder, 2004, The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes., Diabetes Care, 27, 1915, 10.2337/diacare.27.8.1915 · DOI · Paper page
  96. Kolterman, 2005, Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus., Am J Health Syst Pharm, 62, 173, 10.1093/ajhp/62.2.173 · DOI · Paper page
  97. Edwards, 2001, Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers, Am J Physiol Endocrinol Metab, 281, E155, 10.1152/ajpendo.2001.281.1.E155 · DOI · Paper page
  98. Egan, 2002, The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes., J Clin Endocrinol Metab, 87, 1282, 10.1210/jcem.87.3.8337 · doi:10.1210/jcem.87.3.8337 · Paper page
  99. Degn, 2004, Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia., Diabetes, 53, 2397, 10.2337/diabetes.53.9.2397 · DOI · Paper page
  100. Kolterman, 2003, Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes., J Clin Endocrinol Metab, 88, 3082, 10.1210/jc.2002-021545 · DOI · Paper page
  101. Zinman, 2007, The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial., Ann Intern Med, 146, 477, 10.7326/0003-4819-146-7-200704030-00003 · DOI · Paper page
  102. Juhl, 2002, Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes., Diabetes, 51, 424, 10.2337/diabetes.51.2.424 · DOI · Paper page
  103. Chang, 2003, The GLP-1 derivative NN2211 restores β-cell sensitivity to glucose in type 2 diabetic patients after a single dose., Diabetes, 52, 1786, 10.2337/diabetes.52.7.1786 · DOI · Paper page
  104. Madsbad, 2004, Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial., Diabetes Care, 27, 1335, 10.2337/diacare.27.6.1335 · DOI · Paper page
  105. Kim, 2007, Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes., Diabetes Care, 30, 1487, 10.2337/dc06-2375 · DOI · Paper page
  106. Aschner, 2006, Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes., Diabetes Care, 29, 2632, 10.2337/dc06-0703 · DOI · Paper page
  107. Rosenstock, 2006, Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study., Clin Ther, 28, 1556, 10.1016/j.clinthera.2006.10.007 · DOI · Paper page
  108. Zhang, 2007, Continuous stimulation of human glucagon-like peptide-1 (7-36) amide in a mouse model (NOD) delays onset of autoimmune type 1 diabetes., Diabetologia, 50, 1900, 10.1007/s00125-007-0737-6 · DOI
  109. Patriti, 2007, How the hindgut can cure type 2 diabetes. Ileal transposition improves glucose metabolism and β-cell function in Goto-kakizaki rats through an enhanced proglucagon gene expression and L-cell number., Surgery, 142, 74, 10.1016/j.surg.2007.03.001 · DOI
  110. Gedulin, 2005, Exenatide (exendin-4) improves insulin sensitivity and β-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight., Endocrinology, 146, 2069, 10.1210/en.2004-1349 · DOI · Paper page
  111. Mu, 2006, Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic β-cell mass and function in a rodent model of type 2 diabetes., Diabetes, 55, 1695, 10.2337/db05-1602 · DOI · Paper page
  112. Reimer, 2002, Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice., Eur J Endocrinol, 146, 717, 10.1530/eje.0.1460717 · DOI · Paper page

Cited by

See all 109

Metadata

Authors
Salehi, M., Aulinger, B. A., & D'Alessio, D. A.
Venue
Endocrine Reviews
Published
2008-02-21
Volume
29
Issue
3
Pages
367-379
ISSN
  • 0163-769X (ISSN-L)
  • 1945-7189
OpenAlex
W2109432892
Cited by
109
References
49
FWCI
8.28
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.